#None #Heart Failure #Petah-Tikva #Microtech #Medinol

Groundbreaking Implantable Microsensor for Heart Failure

Introduction
In a significant advancement within the realm of cardiac care, Microtech, a fully owned subsidiary of Medinol Inc., has announced the initiation of human clinical trials for its cutting-edge implantable microsensor. This device is designed specifically for monitoring vital heart pressures in patients with heart failure. The inaugural implant was successfully performed by Professor Erez Sharoni at the Beilinson Medical Center in Petah-Tikva, Israel.

The Technology Behind the Microsensor
Microtech's microsensor technology represents years of meticulous development and innovation. This device is not only independent; it can also be seamlessly integrated into existing medical implants. One of its key advantages lies in its ultra-small size, which is sub-millimeter, and its fully passive function that communicates via ultrasound. This unique feature enables existing implants to be upgraded to smart devices, collecting real-time data and executing multiple functions simultaneously.

Expert Insights into the Innovation
Professor Sharoni, who specializes in cardiothoracic surgery, emphasized the potential impact of this new technology. He stated, "This incredible technology has the capacity to redefine care standards for heart failure patients, particularly for those fitted with LVADs (Left Ventricular Assist Devices) or awaiting heart transplants."

Utilization of Collected Data
The data gathered from the implanted sensors will be pivotal for heart failure specialists, aiding in informed clinical decision-making. As explained by Dr. Tuvia Ben-Gal, director of heart failure at Rabin Medical Center, "Heart failure is characterized by inactive periods followed by phases of deterioration, often necessitating repeated hospital admissions. This innovative technology allows us to monitor patient parameters in real time, enabling timely interventions and ultimately reducing morbidity and mortality rates."

Enhanced Access to Healthcare
Dr. Yoram Richter, CEO of Medinol, added that integrating sensors into existing medical devices enables physicians to base patient care on quantifiable physiological parameters rather than just symptoms. This is a crucial step towards equitable healthcare access worldwide. With a compact home unit, a patient with a Microtech-enabled implant can promptly relay accurate pressure readings directly to their physician, thus overcoming geographical barriers or mobility issues.

Broader Applications of the Technology
The unique capabilities of this technology are expected to be transformative across various clinical scenarios, including conditions like glaucoma, hydrocephalus, portal hypertension, and others. By expanding access to healthcare and minimizing the need for office visits or hospital admissions, the microsensor technology will redefine patient-care paradigms.

The Vision of Medinol
Medinol is committed to changing the landscape of disease diagnosis and treatment. With a focus on creating state-of-the-art devices for stent placement, reducing complications in structural cardiac procedures, and providing real-time physiological metrics through implantable sensors, Medinol actively challenges and redefines current technologies and practices. The company’s mission is to pioneer new devices that will enlarge both the physical and geographical scope for medical professionals in patient care.

Conclusion
The initiation of this human trial for the implantable microsensor marks a hopeful chapter in the treatment of heart failure. As these promising technologies evolve, they hold the potential to enhance patient outcomes significantly and redefine the standards of cardiac healthcare for years to come.